Iambic Therapeutics, Inc. IAM
Iambic Therapeutics, Inc. (Nasdaq: IAM) is an oncology drug developer. Its lead program, IAM1363, is in Phase 1 for HER2-altered advanced solid tumors (HER2-positive breast, GEA, HER2-amplified/mutant NSCLC). Its next catalyst on record is IAM-C1: IND submission, then Phase 1/2 initiation (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: IAM-C1 — IND submission, then Phase 1/2 initiation (Q4 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| IAM1363 (HER2 TKI) | HER2-altered solid tumors | small molecule | Phase 1 |
| IAM217 (KIF18A inhibitor) | Ovarian cancer, TNBC, other solid tumors | small molecule | Pre-clinical |
| IAM-C1 (CDK2/4 inhibitor) | Solid tumors | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.